Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JMT103 versus zoledronic acid for prevention of skeletal-related events in patients with bone metastases from solid tumors
CTR20240124Phase 3Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of narlumosbart, zoledronic acid in bone metastases, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Apr 2024; status: active.
02
Drugs
narlumosbartzoledronic acid
03
Conditions
bone metastases
Beyond the preview
Go deeper on CTR20240124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240124.